Shilpa Medicare enters into strategic partnership with NXI Therapeutics AG

Shilpa Medicare and CDMO company, announced the strategic partnership for a long-term development and commercial manufacturing agreement with NXI Therapeutics AG, Switzerland for a novel therapy targeting autoimmune and alloimmune disorders.

The autoimmune and immune-modulation segment represents one of the fastest-growing therapeutic categories globally, driven by increasing prevalence and demand for targeted immunotherapies. By securing this mandate at an early stage, Shilpa enhances its participation in high-value, innovation-driven pipelines with scalable commercial potential.

This partnership marks the third significant international development and manufacturing contract secured by Shilpa group, underscoring strengthening demand from Western biotech companies for its integrated R&D capabilities and advanced GMP manufacturing infrastructure.

At 12.24 pm, Shilpa Medicare was trading at Rs. 325.85, up by 1.10%, with a volume of 5944 shares on the BSE.